Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans

Drug Metabolism and Disposition

Volumn 29, Issue 10, 2001, Pages 1316-1324

  Naritomi, Yoichi ^a   Terashita, Shigeyuki ^a   Kimura, Sumihisa ^a   Suzuki, Akira ^a   Kagayama, Akira ^a   Sugiyama, Yuichi ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DIAZEPAM; DILTIAZEM; FABESETRON; N [1 (2 FLUOROPHENYL) 3,4,6,7 TETRAHYDRO 4 OXOPYRROLO[3,2,1 JK][1,4]BENZODIAZEPIN 3 YL] 1H INDOLE 2 CARBOXAMIDE; NICARDIPINE; NILVADIPINE; OMEPRAZOLE; ZOLPIDEM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCULATION; CONTROLLED STUDY; CORRELATION FUNCTION; DOG; DRUG CLEARANCE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CLEARANCE; LIVER METABOLISM; LIVER MICROSOME; MALE; MATHEMATICAL MODEL; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RAT; RELIABILITY; SPECIES DIFFERENCE;

ANIMALS; BENZODIAZEPINONES; HUMANS; IMIDAZOLES; INDOLES; MALE; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MODELS, ANIMAL; OMEPRAZOLE; PREDICTIVE VALUE OF TESTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0034835463     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Pharmacokinetics of various single intravenous and oral doses of omeprazole
2. Intestinal drug metabolism and anti-transport processes: A potential paradigm shift in oral drug delivery
3. Physiological parameters in laboratory animals and humans
4. Pharmacokinetics of diazepam in the rat: Influence of a carbon tetrachloride-induced hepatic injury
5. Studies on the drug interaction of diltiazem. I. Effects of co-administrated drugs and dosing conditions on the bioavailability of diltiazem
6. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4
7. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species
8. Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro
9. Predicting the hepatic clearance of xenobiotics in humans from in vitro data
10. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
11. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices
12. Metabolic fate of zolpidem(IV): Serum and plasma protein binding of zolpidem and its transfer into the blood cells in rats, monkeys and humans
13. Metabolic fate of zolpidem(I): Pharmacokinetics of zolpidem in rats after single dosing
14. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
15. Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozyme
16. Pharmacokinetics and plasma binding of diazepam in man, dog, rabbit, guinea pig and rat
17. Pharmacokinetic model of diltiazem
18. Phase I study of zolpidem - Single and multiple dose studies
19. Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: Application to 10 extensively metabolized drugs
20. Deacetylation of diltiazem by rat liver
21. Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure
22. Estimation of oral drug absorption in man based on intestine permeability in rats
23. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data
24. Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam
25. Design principles for orally bioavailable drugs
26. Plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man and dog
27. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes
28. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance
29. Oxidative metabolism of zolpidem by human liver cytochrome P-450s
30. Pharmacokinetics of diltiazem in selected animal species and human beings
31. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance
32. Pharmacokinetics and metabolism of omeprazole in animals and man - An overview
33. Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model
34. Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats
35. Xenobiotic metabolism and disposition
36. Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites
37. Multiple-dose pharmacokinetics of nilvadipine in healthy volunteers
38. Absorption, distribution and excretion of nilvadipine, a new dihydropyridine calcium antagonist, in rats and dogs
39. Pharmacokinetics of nilvadipine, a new dihydropyridine calcium antagonist, in mice, rats rabbits and dogs
40. Pharmacokinetics and metabolism of diltiazem in rats following a single intra-arterial or single oral dose
41. First-pass metabolism of omeprazole in rats
42. Clearance approaches in pharmacology